|
RASA2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 8.36659963532327E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.81550000033504E-07 |
| Normal-vs-Stage2 |
1.5553999999085E-07 |
| Normal-vs-Stage3 |
6.13399999682684E-08 |
| Normal-vs-Stage4 |
1.60093000000083E-05 |
| Stage1-vs-Stage2 |
5.231700E-02 |
| Stage1-vs-Stage3 |
2.046600E-01 |
| Stage1-vs-Stage4 |
4.539400E-01 |
| Stage2-vs-Stage3 |
3.352400E-01 |
| Stage2-vs-Stage4 |
2.861200E-01 |
| Stage3-vs-Stage4 |
8.364400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.17240000432994E-08 |
| Normal-vs-AfricanAmerican |
1.127650E-02 |
| Normal-vs-Asian |
1.222840E-04 |
| Caucasian-vs-AfricanAmerican |
5.152400E-01 |
| Caucasian-vs-Asian |
9.674400E-01 |
| AfricanAmerican-vs-Asian |
5.876600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.96919999972955E-07 |
| Normal-vs-Female |
1.60749999977838E-08 |
| Male-vs-Female |
1.947830E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.57225999999344E-05 |
| Normal-vs-Age(41-60Yrs) |
1.03049999644611E-08 |
| Normal-vs-Age(61-80Yrs) |
8.15199996395677E-09 |
| Normal-vs-Age(81-100Yrs) |
5.757900E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.396150E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.690300E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.605000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.932600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.778000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.456000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.041810E-01 |
| Classical-VS-Follicular |
3.0166999998027E-07 |
| Classical-VS-Other |
2.460800E-01 |
| Classical-VS-Normal |
1.035330E-04 |
| Tall-VS-Follicular |
1.083640E-01 |
| Tall-VS-Other |
7.280800E-01 |
| Tall-VS-Normal |
1.66499999999514E-05 |
| Follicular-VS-Other |
6.023800E-01 |
| Follicular-VS-Normal |
3.67640029530492E-10 |
| Other-VS-Normal |
1.355620E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.10860251271106E-11 |
| Normal-vs-N1 |
7.83189999999934E-05 |
| N0-vs-N1 |
1.672170E-01 |
|
|
